CN104815334B - Transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine dilution - Google Patents
Transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine dilution Download PDFInfo
- Publication number
- CN104815334B CN104815334B CN201510184521.1A CN201510184521A CN104815334B CN 104815334 B CN104815334 B CN 104815334B CN 201510184521 A CN201510184521 A CN 201510184521A CN 104815334 B CN104815334 B CN 104815334B
- Authority
- CN
- China
- Prior art keywords
- liquid
- swine
- epidemic diarrhea
- dilution
- live vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of live vaccine dilution, especially transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine dilution, including A liquid and B liquid, KCl, 3.58g of NaCl, 0.2g containing 8g Na in every liter of A liquid2HPO4·12H2O, 0.24g KH2PO4, B liquid is except containing material in A liquid, being additionally added astragalus polyose, propolis, Tween 80 and mineral oil, and A liquid is well mixed with B liquid in mass ratio 1: 1 when using.Transmissible gastroenteritis of swine that the present invention is provided, epidemic diarrhea bigeminal live vaccine dilution, can improve immune effect of vaccine, swinery is obtained more preferable immune protective efficiency.
Description
Technical field
The present invention relates to a kind of live vaccine dilution, especially transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine is dilute
Release liquid.
Background technology
Pig epidemic diarrhea is worldwide widely current with transmissible gastroenteritis of swine, especially in South Korea, and Japan is with
Guo Deng Asian countries.It brings serious economic loss to pig industry.PED causes that the survival rate of pig is reduced, regularity is poor, subtract
The slow speed of growth, weightening reduce, postpone Time To Market, reduction efficiency of feed utilization, the extra consumption of increase, reduction livestock premunition,
Increase is to bacterium, the neurological susceptibility of virus, the increase incidence of disease, body weight that raising medical expense, livestock are dehydrated, suffered a shock, dead, pig has loose bowels
The serious consequences such as decline.
At present, for pig epidemic diarrhea and transmissible gastroenteritis of swine also without definite effective treatment method, therefore to this
The prevention and control of two kinds of diseases, many policies using " putting prevention first, support anti-combination ".In order to effectively control pig epidemic diarrhea and pig
Transmissible gastroenteritis, China has developed the vaccine for preventing and treating pig epidemic diarrhea and transmissible gastroenteritis of swine, but to it
Diluent, especially while it is less suitable for transmissible gastroenteritis of swine, the research of epidemic diarrhea bigeminal live vaccine dilution, it is existing
Vaccine diluent effect it is also not good for the effect of transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine.
The content of the invention
For above-mentioned technical problem, it is dilute that the present invention provides a kind of transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine
Liquid is released, immune effect of vaccine can be improved, swinery is obtained more preferable immune protective efficiency.Concrete technical scheme is：
Transmissible gastroenteritis of swine, epidemic diarrhea live vaccine dilution, gained is prepared by following steps：
(1) prepared by A liquid
KCl, 3.58g of NaCl, 0.2g containing 8g Na in every liter of A liquid2HPO4·12H2O, 0.24g KH2PO4, the above
Material is dissolved in water for injection, and sterilization treatment is carried out under 121 DEG C of temperature, 100 kPas of pressure conditions；
(2) prepared by B liquid
Aqueous phase：KCl, 3.58g of NaCl, 0.2g containing 8g Na in every liter of water2HPO4·12H2O, 0.24g's
KH2PO4, above material is dissolved in water for injection；Add astragalus polyose concentration after astragalus polyose, propolis, Tween 80, addition
For 0.5~5%w/v, propolis concentration is 10~100mg/ml, and Tween 80 concentration is 1~5%w/v, standby after filtration sterilization；
Oil phase：It is standby after 121 DEG C, 100 kPas pressure sterilizings of mineral oil；
Oil phase is slowly added in aqueous phase and stirred, oil phase is with aqueous phase weight than 1: 2, and oil phase addition reuses height after finishing
Emulsification pretreatment machine obtains B liquid with 4000r/min emulsification treatments 30min；
(3) use of dilution：A liquid is well mixed with B liquid in mass ratio 1: 1 when using.
Transmissible gastroenteritis of swine that the present invention is provided, epidemic diarrhea bigeminal live vaccine dilution, can improve vaccine and exempt from
Epidemic disease effect, makes swinery obtain more preferable immune protective efficiency.
Brief description of the drawings
The age in days piglet TGE neutralize antibody titers of Fig. 1 1~3；
The age in days piglet PED neutralize antibody titers of Fig. 2 1~3；
Fig. 3 sow TGE neutralize antibody titers；
Fig. 4 sow PED neutralize antibody titers.
Embodiment
It is described in conjunction with the embodiments the embodiment of the present invention.
Transmissible gastroenteritis of swine, epidemic diarrhea live vaccine dilution, gained is prepared by following steps：
(1) prepared by A liquid
KCl, 3.58g of NaCl, 0.2g containing 8g Na in every liter of A liquid2HPO4·12H2O, 0.24g KH2PO4, the above
Material is dissolved in water for injection, and sterilization treatment is carried out under 121 DEG C of temperature, 100 kPas of pressure conditions；
(2) prepared by B liquid
Aqueous phase：KCl, 3.58g of NaCl, 0.2g containing 8g Na in every liter of water2HPO4·12H2O, 0.24g's
KH2PO4, above material is dissolved in water for injection；Add astragalus polyose concentration after astragalus polyose, propolis, Tween 80, addition
For 0.5~5%w/v, propolis concentration is 10~100mg/ml, and Tween 80 concentration is 1~5%w/v, standby after filtration sterilization；
Oil phase：It is standby after 121 DEG C, 100 kPas pressure sterilizings of mineral oil；
Oil phase is slowly added in aqueous phase and stirred, oil phase is with aqueous phase weight than 1: 2, and oil phase addition reuses height after finishing
Emulsification pretreatment machine obtains B liquid with 4000r/min emulsification treatments 30min；
(3) use of dilution：A liquid is well mixed with B liquid in mass ratio 1: 1 when using.
Dilution obtained by above example and comparison example are subjected to contrast experiment：
1st, vaccine dilutes：Using dilution, phosphate buffer PBS made from the present embodiment respectively by transmissible gastroenteric
Scorching, epidemic diarrhea bigeminal live vaccine is diluted to 1 part/ml.
2nd, contrast is immunized
(1) 1~3 age in days piglet：1~3 age in days piglet 15, is divided into A1, B1, C13 group, every group 5.
A1 groups inject the vaccine after diluted made from existing the present embodiment, 1.0ml/ heads；The injection PBS dilutions of B1 groups
Vaccine afterwards, 1.0ml/ heads；C1 groups injection PBS is used as blank control group, 1.0ml/ heads.0th, 7,14,21,28 and 35 after immune
Its separation serum of taking a blood sample respectively, determines PED and TGE neutralize antibody titers, calculates the geometrical mean of every group of piglet antibody titer
And carry out comparative analysis.
(2) sow：Antenatal 28~35 age in days sow 15, is divided into A2, B2, C23 group, every group 5.The injection of A2 groups group is implemented
Vaccine after the obtained diluted of example；Vaccine after the injection PBS dilutions of B2 groups, 1.0ml/ heads；C2 groups injection PBS is used as sky
White control group, 1.0ml/ heads.Immune rear 0th, 14,28,35 take a blood sample respectively separates serum, determines PED and TGE neutralizing antibodies effect
Valency, calculates the geometrical mean of every group of sow antibody titer and carries out comparative analysis.
3rd, interpretation of result
(1) 1~3 age in days piglet：The TGE that the age in days of dilution group 1~3 is 7th after immune, 14,21,28 and 35 days produce resists
Body level is apparently higher than PBS groups and blank control group；7th after immune, PED antibody levels that 14,21,28 and 35 days produce it is obvious
Higher than PBS groups and blank control group, and after vaccine immunity, the 7th day dilution group PED antibody titers geometrical mean is higher than 1
: 32, as a result see Fig. 1 and Fig. 2.
(2) sow：Dilution group sow is immunized rear 14th, 28,35 and produces same day TGE antibody levels apparently higher than PBS
Group and blank control group；14th after immune, 28 and 35 days PED antibody levels apparently higher than PBS groups and control group, as a result see Fig. 3
And Fig. 4.Sow PED and TGE High antibody level, contribute to primiparity piglet by maternal antibody obtain protection so that reduce or
Person mitigates the disease even death caused by transmissible gastroenteritis or epidemic diarrhea.
Claims (1)
1. transmissible gastroenteritis of swine, epidemic diarrhea live vaccine dilution, it is characterised in that prepare gained by following steps：
(1) prepared by A liquid
KCl, 3.58g of NaCl, 0.2g containing 8g Na in every liter of A liquid2HPO4·12H2O, 0.24g KH2PO4, above material
It is dissolved in water for injection, sterilization treatment is carried out under 121 DEG C of temperature, 100 kPas of pressure conditions；
(2) prepared by B liquid
Aqueous phase：KCl, 3.58g of NaCl, 0.2g containing 8g Na in every liter of water2HPO4·12H2O, 0.24g KH2PO4, with
Upper material is dissolved in water for injection；Add after astragalus polyose, propolis, Tween 80, addition astragalus polyose concentration be 0.5~
5%w/v, propolis concentration is 10~100mg/ml, and Tween 80 concentration is 1~5%w/v, standby after filtration sterilization；
Oil phase：It is standby after 121 DEG C, 100 kPas pressure sterilizings of mineral oil；
Oil phase is slowly added in aqueous phase and stirred, oil phase is with aqueous phase weight than 1: 2, and oil phase addition reuses high shear after finishing
Mulser obtains B liquid with 4000r/min emulsification treatments 30min；
(3) use of dilution：A liquid is well mixed with B liquid in mass ratio 1: 1 when using.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510184521.1A CN104815334B (en) | 2015-04-17 | 2015-04-17 | Transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine dilution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510184521.1A CN104815334B (en) | 2015-04-17 | 2015-04-17 | Transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine dilution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104815334A CN104815334A (en) | 2015-08-05 |
| CN104815334B true CN104815334B (en) | 2017-09-26 |
Family
ID=53725966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510184521.1A Active CN104815334B (en) | 2015-04-17 | 2015-04-17 | Transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine dilution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104815334B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474246A (en) * | 2009-01-23 | 2009-07-08 | 北京伟嘉人生物技术有限公司 | Pharmaceutical composition for enhancing immunity of fowl and coordinating with vaccine for synergy |
| CN101690809A (en) * | 2009-09-30 | 2010-04-07 | 西北农林科技大学 | Propolis-astragalus polysaccharides compound nanometer emulsion adjuvant and preparation method and application thereof |
| CN102406936A (en) * | 2011-11-22 | 2012-04-11 | 青岛易邦生物工程有限公司 | Chicken infectious coryza inactivated vaccine adjuvant |
| CN104147599A (en) * | 2014-06-24 | 2014-11-19 | 华中科技大学 | Vaccine adjuvant as well as preparation method and application thereof |
-
2015
- 2015-04-17 CN CN201510184521.1A patent/CN104815334B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474246A (en) * | 2009-01-23 | 2009-07-08 | 北京伟嘉人生物技术有限公司 | Pharmaceutical composition for enhancing immunity of fowl and coordinating with vaccine for synergy |
| CN101690809A (en) * | 2009-09-30 | 2010-04-07 | 西北农林科技大学 | Propolis-astragalus polysaccharides compound nanometer emulsion adjuvant and preparation method and application thereof |
| CN102406936A (en) * | 2011-11-22 | 2012-04-11 | 青岛易邦生物工程有限公司 | Chicken infectious coryza inactivated vaccine adjuvant |
| CN104147599A (en) * | 2014-06-24 | 2014-11-19 | 华中科技大学 | Vaccine adjuvant as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104815334A (en) | 2015-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Johnson et al. | Protective effect of killed trypanosome vaccines with incorporated adjuvants | |
| CN102086447A (en) | Duck virus hepatitis strains and inactivated vaccine | |
| CN106540248A (en) | A kind of vaccine combination of resistant to foot and mouth disease and its preparation method and application | |
| CN103694348A (en) | Preparation and application method for treating swine viral diarrhea biological agent | |
| CN101113176A (en) | Method for preparing infectious chicken Fabricius bursa refined yolk cryodesiccation antibody | |
| CN104815334B (en) | Transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine dilution | |
| CN103830724B (en) | Muscovy duck parvovirus inactivation vaccine and application thereof | |
| CN102793920B (en) | Compound immunopotentiator, inactivated vaccine for poultry, and preparation method thereof | |
| CN102961742A (en) | Bivalent inactivated vaccine of porcine circovirus type 2 and porcine parvovirus and preparation method thereof | |
| CN103122336B (en) | Goose parvovirus H-strain and application thereof in preventing and treating gosling plague | |
| CN102363041A (en) | Method for preparing preservative-free vaccine | |
| CN104434982A (en) | Medicinal globefish oil making method | |
| CN101703766A (en) | Oil-adjuvant vaccine of larvae membrane protein of cryptocaryon irritans, preparation method and applications thereof | |
| CN101948537B (en) | Method for extracting chicken yolk antibody against infectious bursal disease | |
| DE1492243C3 (en) | Injectable vaccines | |
| CN103341163B (en) | Rabies, tetanus economic benefits and social benefits horse anteserum and preparation method thereof | |
| CN107661489A (en) | Vaccine Chinese traditional immunopoteniators and preparation method and application | |
| CN104288766A (en) | Vaccine composition, and preparation method and application thereof | |
| CN105031645B (en) | A kind of Antirabic Vaccine and preparation method thereof | |
| CN103143012A (en) | Traditional Chinese medicine composition and applications in preparation of porcine pseudorabies vaccine immunopotentiator | |
| CN104623653A (en) | Vaccine composition and preparation method thereof | |
| Salat et al. | Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs | |
| CN102085366B (en) | Compound vaccine adjuvant | |
| RU2504400C1 (en) | Inactivated emulsion associated vaccine for cattle parainfluenza-3, infectious rhinotracheitis and viral diarrhoea | |
| CN106434570A (en) | RV (rabies virus) splitting solution and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 641400 Shipan Food and Pharmaceutical Industrial Park, Jianyang Economic Development Zone, Ziyang City, Sichuan Province Patentee after: HUAPAI BIOENGINEERING GROUP CO.,LTD. Address before: 641402 Food and Pharmaceutical Industrial Park, Shipan Economic Development Zone, Jianyang City, Ziyang City, Sichuan Province Patentee before: SICHUAN HUAPAI BIO-PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 641400 Shipan food and pharmaceutical industrial park, Jianyang Economic Development Zone, Ziyang City, Sichuan Province Patentee after: Huapai Biotechnology (Group) Co.,Ltd. Address before: 641400 Shipan food and pharmaceutical industrial park, Jianyang Economic Development Zone, Ziyang City, Sichuan Province Patentee before: HUAPAI BIOENGINEERING GROUP CO.,LTD. |
|
| CP01 | Change in the name or title of a patent holder |